Drugs / Levo-Praziquantel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02315352 | Apr → May 2015 | — | Merck KGaA, Darmstadt, Germany | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levo-Praziquantel | “Levo-Praziquantel (L-PZQ) ODT 150 mg” PMID 34106922 ↗ Jun 2021 |
| Known as | L-PZQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02315352 ↗ |
| Route | Oral | “put and disintegrated in the mouth without water” NCT02315352 ↗ |